Molecular triaging options for women testing HPV positive with self-collected samples.

Cervical screening cervical cancer elimination molecular tests self-collection triage

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 23 06 2023
accepted: 28 08 2023
medline: 9 10 2023
pubmed: 9 10 2023
entrez: 9 10 2023
Statut: epublish

Résumé

We review developments in molecular triaging options for women who test positive for high-risk human papillomavirus (hrHPV) on self-collected samples in the context of cervical cancer elimination. The World Health Organization (WHO) recommends hrHPV screening as the primary test for cervical screening due to its high sensitivity compared to other screening tests. However, when hrHPV testing is used alone for treatment decisions, a proportion of women of childbearing age receive unnecessary treatments. This provides the incentive to optimize screening regimes to minimize the risk of overtreatment in women of reproductive age. Molecular biomarkers can potentially enhance the accuracy and efficiency of screening and triage. HrHPV testing is currently the only screening test that allows triage with molecular methods using the same sample. Additionally, offering self-collected hrHPV tests to women has been reported to increase screening coverage. This creates an opportunity to focus health resources on linking screen-positive women to diagnosis and treatment. Adding an additional test to the screening algorithm (a triage test) may improve the test's positive predictive value (PPV) and offer a better balance of benefits and risks for women. Conventional triage methods like cytology and visual inspection with acetic acid (VIA) cannot be performed on self-collected samples and require additional clinic visits and subjective interpretations. Molecular triaging using methods like partial and extended genotyping, methylation tests, detection of E6/E7 proteins, and hrHPV viral load in the same sample as the hrHPV test may improve the prediction of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and invasive cancer, offering more precise, efficient, and cost-effective screening regimes. More research is needed to determine if self-collected samples are effective and cost-efficient for diverse populations and in comparison to other triage methods. The implementation of molecular triaging could improve screening accuracy and reduce the need for multiple clinical visits. These important factors play a crucial role in achieving the global goal of eliminating cervical cancer as a public health problem.

Identifiants

pubmed: 37810963
doi: 10.3389/fonc.2023.1243888
pmc: PMC10560038
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1243888

Informations de copyright

Copyright © 2023 Taghavi, Zhao, Downham, Baena and Basu.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMC Cancer. 2022 Aug 6;22(1):862
pubmed: 35933332
Int J Cancer. 2019 Jan 1;144(1):34-42
pubmed: 29943809
Int J Cancer. 2015 Aug 15;137(4):859-67
pubmed: 25631198
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
Int J Cancer. 2017 Sep 15;141(6):1110-1119
pubmed: 28560716
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:267-273
pubmed: 30048921
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
Int J Cancer. 2017 Aug 1;141(3):519-530
pubmed: 28470689
BMJ. 2018 Dec 5;363:k4823
pubmed: 30518635
J Med Screen. 2016 Jun;23(2):104-10
pubmed: 26566949
J Low Genit Tract Dis. 2018 Apr;22(2):91-96
pubmed: 29570563
Infect Agent Cancer. 2020 Feb 07;15:9
pubmed: 32047531
Carcinogenesis. 2010 Nov;31(11):1905-12
pubmed: 20819779
Gynecol Oncol. 2021 Sep;162(3):575-583
pubmed: 34172287
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell. 2017 Sep 7;170(6):1164-1174.e6
pubmed: 28886384
Int J Mol Sci. 2018 Jun 08;19(6):
pubmed: 29890655
EBioMedicine. 2019 Dec;50:246-259
pubmed: 31732479
Cancer Prev Res (Phila). 2018 Mar;11(3):165-170
pubmed: 29437696
Int J Cancer. 2022 Jan 15;150(2):290-302
pubmed: 34562270
Int J Cancer. 2019 May 15;144(10):2587-2595
pubmed: 30412281
JAMA. 2020 Oct 20;324(15):1532-1542
pubmed: 33079153
J Natl Cancer Inst. 2021 Mar 1;113(3):292-300
pubmed: 32745170
Cancer Med. 2020 Sep;9(18):6813-6824
pubmed: 32706163
Br J Cancer. 2019 Nov;121(11):954-965
pubmed: 31616037
HIV Med. 2023 Aug;24(8):877-892
pubmed: 37062862
Int J Cancer. 2019 Oct 15;145(8):2042-2050
pubmed: 30684396
Cancer Epidemiol Biomarkers Prev. 2021 Feb;30(2):268-277
pubmed: 33219163
PLoS Pathog. 2017 Apr 6;13(4):e1006211
pubmed: 28384274
BMC Cancer. 2022 Jan 6;22(1):42
pubmed: 34991494
BMJ Open. 2019 Sep 6;9(9):e029088
pubmed: 31494606
Viruses. 2017 Dec 19;9(12):
pubmed: 29257060
BMC Cancer. 2019 Jan 30;19(1):111
pubmed: 30700274
Nat Cancer. 2021 Feb;2(2):133-134
pubmed: 35122078
Arch Pathol Lab Med. 2012 Oct;136(10):1266-97
pubmed: 22742517
Int J Cancer. 2020 Sep 1;147(5):1275-1285
pubmed: 31970767
BJOG. 2021 Feb;128(3):504-514
pubmed: 32619334
Clin Microbiol Infect. 2021 Aug;27(8):1083-1095
pubmed: 33975008
Front Med (Lausanne). 2023 Feb 21;10:1111269
pubmed: 36895724
Int J Gynaecol Obstet. 2016 Mar;132(3):259-65
pubmed: 26851054
J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S1-S27
pubmed: 23519301
BMJ Glob Health. 2021 May;6(5):
pubmed: 34011537
Int J Cancer. 2018 Aug 15;143(4):813-822
pubmed: 29524206
Cancers (Basel). 2020 Apr 24;12(4):
pubmed: 32344565
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2651-2661
pubmed: 32943435
BJOG. 2020 May;127(6):729-736
pubmed: 31880054
Int J Cancer. 2016 Mar 15;138(6):1453-61
pubmed: 26421807
JCO Glob Oncol. 2020 Apr;6:658-666
pubmed: 32343627
Infect Agent Cancer. 2022 Jun 11;17(1):27
pubmed: 35690793
Cancer Sci. 2018 Jun;109(6):2003-2012
pubmed: 29660849
Am J Obstet Gynecol. 2015 Jun;212(6):769.e1-7
pubmed: 25582099
Int J Cancer. 2007 Aug 1;121(3):621-32
pubmed: 17405118
Lancet Oncol. 2014 Feb;15(2):172-83
pubmed: 24433684
Gynecol Oncol. 2019 Apr;153(1):26-33
pubmed: 30638767
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
Br J Cancer. 2003 Jul 7;89(1):101-5
pubmed: 12838308
Int J Cancer. 2017 Aug 1;141(3):437-446
pubmed: 28297074
Dis Markers. 2007;23(4):315-30
pubmed: 17627065
Cell Host Microbe. 2014 Mar 12;15(3):266-82
pubmed: 24629334
Int J Cancer. 2016 Dec 1;139(11):2606-15
pubmed: 27509172
EClinicalMedicine. 2022 Sep 27;53:101645
pubmed: 36187721
J Gynecol Oncol. 2021 Nov;32(6):e86
pubmed: 34708593
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99
pubmed: 23199969
Lancet. 2006 Feb 11;367(9509):489-98
pubmed: 16473126
J Low Genit Tract Dis. 2020 Apr;24(2):144-147
pubmed: 32243309
Ann Intern Med. 2017 Jan 17;166(2):118-127
pubmed: 27842420
BMJ Glob Health. 2019 May 14;4(3):e001351
pubmed: 31179035
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731
J Pathol. 2006 Jan;208(2):152-64
pubmed: 16362994
Lancet Glob Health. 2022 Aug;10(8):e1115-e1127
pubmed: 35839811
Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
pubmed: 23199964
Acta Cytol. 2016;60(6):501-512
pubmed: 27806357
Br J Cancer. 2003 Jan 13;88(1):63-73
pubmed: 12556961
AIDS. 2006 Nov 28;20(18):2337-44
pubmed: 17117020
Lancet Glob Health. 2020 Feb;8(2):e296-e304
pubmed: 31981559
Nat Rev Cancer. 2010 Oct;10(10):707-19
pubmed: 20865011
Prev Med. 2021 Mar;144:106399
pubmed: 33388322
Lancet Public Health. 2020 Aug;5(8):e425
pubmed: 32673570
Gynecol Oncol. 2019 Aug;154(2):360-367
pubmed: 31160073
Int J Cancer. 2023 Apr 15;152(8):1581-1592
pubmed: 36451311
Clin Cancer Res. 2018 May 1;24(9):2194-2202
pubmed: 29420222
BMJ. 2014 Sep 16;349:g5264
pubmed: 25232064

Auteurs

Katayoun Taghavi (K)

Early Detection, Prevention and Infections Branch, International Agency For Research On Cancer (IARC), Lyon, France.

Fanghui Zhao (F)

Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Laura Downham (L)

Early Detection, Prevention and Infections Branch, International Agency For Research On Cancer (IARC), Lyon, France.

Armando Baena (A)

Early Detection, Prevention and Infections Branch, International Agency For Research On Cancer (IARC), Lyon, France.

Partha Basu (P)

Early Detection, Prevention and Infections Branch, International Agency For Research On Cancer (IARC), Lyon, France.

Classifications MeSH